Research Portfolio

Funding Opportunities

Join our Mailing List
Join our mailing list to be notified of new funding opportunities.

Your Email

To receive information about funding opportunities, events, and program updates.



Cytokine gene-modified dendritic cells for lung cancer

Institution: University of California, Los Angeles
Investigator(s): Steven Dubinett, M.D.
Award Cycle: 2000 (Cycle 9) Grant #: 9RT-0118 Award: $590,523
Subject Area: Cancer
Award Type: Research Project Awards
Abstracts

Initial Award Abstract
Lung cancer is the leading cause of cancer death in men and women in the United States. New therapies are needed for lung cancer to either prevent or treat its spread throughout the body. This research focuses on boosting the immune system against lung cancer by using specialized immune enhancing cells called dendritic cells. This new form of therapy uses dendritic cells that are removed from the blood, activated in test tubes, and then injected into lung tumors. We have found that this form of therapy is able to completely cure mice with cancer. This research focuses on testing the safety and immune-enhancing capacity of dendritic cell immunotherapy for patients with lung cancer. Thus, results of this study may have a major impact on the treatment of lung cancer.
Publications

Secondary lymphoid chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalvelolar cell carcinoma.
Periodical: Cancer Research Index Medicus:
Authors: Sharma S, Stolina M, Zhu L, Lin Y, Batra R, Huang M, Strieter R, and Dubinett SM ART
Yr: 2001 Vol: 61 Nbr: Abs: Pg: 6406-6412

Interleukin-7 inhibits both TGF-beta production and signaling in pulmonary fibrosis fibroblsts.
Periodical: Journal of Clinical Investigation Index Medicus:
Authors: Huang M, Sharma S, Zhu SX, Luo J, Keane MP, Burdick MD, Lin YQ et al ART
Yr: 2002 Vol: 109 Nbr: Abs: Pg: 931-937

Characterization of adenoviral CCl-21/SLC for intratumoral dentrictic cell (DC) based therapies in NSCLC.
Periodical: American Association for Cancer Research Index Medicus:
Authors: Riedl K, Baratelli F, Yang SC, Luo J, Escuadro B, Batra RK, Figlin R, Dubinett SM, et al. ABS
Yr: 0 Vol: 44 Nbr: 417 Abs: Pg:

Non-small cell lung cancer-derived soluble mediators enhance apoptosis in T lymphocytes through an I kappa B kinase-dependent mechanism
Periodical: Cancer Research Index Medicus:
Authors: Batra R, Lin Y, Gardner B, Luo J, Dohadwala M, Sharma S, Dubinett S ART
Yr: 2003 Vol: 63 Nbr: Abs: Pg: 642-646

Abnormal IL-10Ralpha expression contributes to the maintenance of elevated COX-2 in non-small cell lung cancer cells.
Periodical: Cancer Research Index Medicus:
Authors: Heuze-Vourc'h N, Zhu L, Krysan K, Batra RK, Sharma S, Dubinett S ART
Yr: 2003 Vol: 63 Nbr: Abs: Pg: 766-770

Tumor COX-2-dependent regulation of murine dendritic cell function.
Periodical: Clinical Cancer Research Index Medicus:
Authors: Sharma S, Stolina M, Baratelli F, Lin JF, Zhu L, Lin Y, Batra RK, Dubinett S, et al. ART
Yr: 2003 Vol: 9 Nbr: Abs: Pg: 961-968

IL-10 mediates the sigma receptor-dependent suppression of antitumor immunity.
Periodical: Journal of Immunology Index Medicus:
Authors: Zhu LX, Sharma S, Gardner B, Escuadro B, Atianzar K, Tashkin D, Dubinett S ART
Yr: 2003 Vol: 170 Nbr: Abs: Pg: 3585-3591

The secondary lymphoid tissue chemokine (SLC)-mediated antitumor response requi4res the in vivo induction of interferon inducible protein-10 (IP-10) and monokine induced by interferon gamma (MIG).
Periodical: Molecular Cancer Research Index Medicus:
Authors: Sharma S, Yang C, Zhu LX, Batra RK, Strieter RM, Dubinett S ART
Yr: 2003 Vol: 2 Nbr: Abs: Pg: 22

Non-radioactive iodide effectively induces apoptosis in genetically modified lung cancer cells.
Periodical: Cancer Research Index Medicus:
Authors: Zhang I, Sharma S, Zhu LX, Kogai T, Hershman JM, Brent GA, Dubinett SM, Huang M ART
Yr: 2003 Vol: 63 Nbr: Abs: Pg: 5065-5072

Methanandamide increases COX-2 expression and tumor growth in murine lung cancer.
Periodical: FASEB Journal Index Medicus:
Authors: Gardner B, Zhui L, Sharma S, Tashkin DP, Dubinett SM ART
Yr: 2003 Vol: 17 Nbr: 14 Abs: Pg: 2157-2159

IL-7 gene modified dentritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
Periodical: Human Gene Therapy Index Medicus:
Authors: Sharma S, Batra RK, Yang SC, Hillinger S, Zhu L, Atianzar K, Dubinett SM, et al. ART
Yr: 2003 Vol: 14 Nbr: Abs: Pg: 1511-1524

Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells.
Periodical: Molecular Cancer Research Index Medicus:
Authors: Riedl K, Baratelli F, Batra R, Yang SC, Luo J, Escuadro B, Figlin R, Dubinett SM ART
Yr: 2003 Vol: 2 Nbr: Abs: Pg: 35

COX-2-dependent stabilization of survivin in non-small cell lung cancer.
Periodical: FASEB Journal Index Medicus:
Authors: Krysan K, Merchant FH, Zhu L, Dohadwala M. Luo J, et al. ART
Yr: 2004 Vol: 18 Nbr: 1 Abs: Pg: 206-208

Epstein barr virus-induced molecule I ligand chemokine (ELC/CCL19) promotes IFNy-dependent antitumor responses in a lung cancer model.
Periodical: Journal of Immunology Index Medicus:
Authors: Hillinger S, Yang SC, Zhu L, Huang M, Duckett R, Dubinett SM, et al. ART
Yr: 2003 Vol: 171 Nbr: Abs: Pg: 6456-6457

Celecoxib modulates the capacity for PGE2 and IL-10 production in alveolar macrophages.
Periodical: Clinical Cancer Research Index Medicus:
Authors: Mao JT, Roth MD, Serio KJ, Baratelli F, Zhu L, Holmes EC, Strieter RM, Dubinett SM ART
Yr: 2003 Vol: 9 Nbr: 5835-5841 Abs: Pg:

Cyclooxygenase-2 in lung cancer.
Periodical: Prog Exp Tumor Research Index Medicus:
Authors: Dubinett SM, Sharma S, Huang M, Pold M. Mao JT ART
Yr: 2003 Vol: 37 Nbr: Abs: Pg: 138-162

Cyclooxygenase-2 dependent expression of angiogenic CXC chemokines, ENA-78/CXCL5 and IL-8/CXCL8, in human non-small cell lung cancer.
Periodical: Cancer Research Index Medicus:
Authors: Pold M, Zhu L, Sharma S, Burdick M, Dubinett SM, et al. ART
Yr: 2004 Vol: 64 Nbr: Abs: Pg: 1853-1860

Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
Periodical: Clinical Cancer Research Index Medicus:
Authors: Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Dubinett SM, et al. ART
Yr: 2004 Vol: 10 Nbr: Abs: Pg: 2891-2901

Cyclooxygenase-2-dependent expression of survivin in non-small cell lng cancer.
Periodical: Chest Index Medicus:
Authors: Krysan K. Dohadwala M, Luo J, Lin Y, Zhu L, Heuze-Vourc'h N, Dubinett SM, et al. ART
Yr: 2004 Vol: 125 Nbr: 5 Suppl Abs: Pg: 140S

IL-7 and TGF-Beta play counter-regulatory roles in PKC-8-dependent control of fibroblast collagen synthesis in pulmonary fibrosis.
Periodical: Journal of Biological Chemistry Index Medicus:
Authors: Zhang L, Keane MP, Zhu LX, Sharma S, Rozengurt E. Strieter RM, Dubinett SM, et al. ART
Yr: 2004 Vol: 279 Nbr: 27 Abs: Pg: 28315-28319

Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small cell lung cancer.
Periodical: Cancer Research Index Medicus:
Authors: Pold M, Krysan K, Pold A, Dohadwala M, Dubinett SM, et al. ART
Yr: 2004 Vol: 64 Nbr: Abs: Pg: 6549-6555

Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.
Periodical: Cancer Research Index Medicus:
Authors: Krysan K, Dalwadi II, Sharma S, Pold M, Dubinett SM ART
Yr: 2004 Vol: 64 Nbr: Abs: Pg: 6359-6362

Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-I production limits dendritic cell migration through extracellular matrix.
Periodical: Journal of Immunology Index Medicus:
Authors: Baratelli F, Heuze-Vourc'h N, Drysan K, Dubinett SM, et al. ART
Yr: 2004 Vol: 173 Nbr: Abs: Pg: 5458-5466

Modulation of pulmonary leukotriene B4 production by cyclooygenase-2 inhibitors and lipopolysaccharide.
Periodical: Clinical Cancer Research Index Medicus:
Authors: Mao JT, Tsu IH, Dubinett SM, et al. ART
Yr: 2004 Vol: 10 Nbr: Abs: Pg: 6872-6878